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ABSTRACT  
The biochemical and toxicological effects of aqueous extract of Parquetina nigrescens leaves (AEPNL) at the doses of 50, 100, and 200 mg/kg 
body weight on mifepristone-induced in Polycystic Ovarian Syndrome (PCOS) was investigated in female Wistar rats. Sixty female Wistar rats 
(190.00 ± 13.00 g) were assigned into 6 groups (A - F) of ten each: animals in group A received 0.5 ml of distilled water orally on daily basis for 
30 days while the mifepristonized rats in groups B, C, D and E also received orally 0.5 ml of distilled water, 7.14mg/kg of metformin (reference 
drug) and same volume of the extract corresponding to 50, 100, and 200 mg/kg body weight of AEPNL respectively after which levels of some 
biochemical and toxicological indices were determined. AEPNL aggravated mifepristone-treatment related increases in albumin, total protein 
and liver aspartate aminotransferase activity and mitigated the increases in globulin, total bilirubin, urea, creatinine, liver and serum alkaline 
phosphatase and alanine aminotransferase activities, and no treatment-related histoarchitectural changes occurred in the liver, kidney and 
uterus of the female rats. Therefore, the aqueous extract of Parquetina nigrescens leaves attenuated and also aggravated some biochemical 
parameters in the serum, liver and kidney but with no histological changes in the liver, kidney and uterus of the mifepristonized female Wistar 
rats. 
Keywords: Mifepristone, toxicology, Parquetina nigrescens, Polycystic Ovarian Syndrome, histology 
 
Article Info: Received 05 Feb 2020;     Review Completed 18 March 2020;     Accepted 29 March 2020;     Available online 15 April 2020 
Cite this article as: 
Femi-olabisi FJ, Faokunla O, Agboola AO, Olorunyolemi IM, Biochemical and Toxicological Evaluations of Aqueous Extract 
of Parquetina nigrescens (Afzel.) leaves on Mifepristone-induced Polycystic Ovarian Syndrome in Rats, Journal of Drug 
Delivery and Therapeutics. 2020; 10(2-s):94-101     http://dx.doi.org/10.22270/jddt.v10i2-s.3956          
*Address for Correspondence:  
Femi-olabisi Fehintoluwa Joy, Biochemistry Unit, Department of Biological Sciences, Mountain Top University, Ogun, Nigeria 
 
  
INTRODUCTION 
Medicinal plants are important elements of indigenous 
medical system in all countries of the world [1]. The general 
acceptability of phytomedicines is, however, limited by lack 
of dose regimen and adequate toxicity or safety [2]. 
Polycystic ovarian syndrome (PCOS), which was formally 
called Stein-Leventhal syndrome or functional ovarian 
hyperandrogenism, is a disorder that is characterised by  
chronic anovulation [3], enlarged ovaries containing 
follicular cysts at different stages of growth, atresia and 
clinical and/or biochemical evidence of ovarian 
hyperandrogenism. PCOS is thought to be one of the leading 
causes of female subfertility [4]. Many plants with 
hypoglycaemic and anti-obesity activities have also been 
reported to be used in the management of PCOS [5]. It has 
been reported over the years that the leaf decoctions of P. 
nigrescens have been used for the treatment of gonorrhea 
and menstrual disorders [6].  The current therapeutic 
approach to treating PCOS involves use of insulin sensitizers 
such as metformin and letrozole, since the central core of 
PCOS etiologies is through insulin resistance. Other 
therapeutic agents that have been used to manage PCOS 
includes metformin, clomiphene citrate, tamoxifen and 
troglitazone [7] [8]. Plant extracts as potential 
phytotherapeutic products are supposed to be safe. 
However, adverse and untoward fatal effects have been 
reported on plant such as, Parquetina nigrescens [9]. Toxicity 
associated with herbal products [10] [11] has alerted many 
national [12] and international regulatory authorities [13] to 
develop and implement various sets of guidelines for 
assessing, monitoring, and preventing the toxicity associated 
with such herbal products [14]. Toxicity tests are most 
widely used to examine specific adverse events or specific 
endpoints [15] such as cancer, cardiotoxicity and skin/eye 
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irritation, etc. Therefore, toxicological evaluation of this 
botanicals with fertility-enhancing activity to ascertain their 
safety as oral remedies in normal experimental animals and 
those induced with the PCOS condition is thus, needed to 
increase their acceptability. 
Parquetina nigrescens (Afzel.) Bullock also known as Ogbo 
(yoruba), Kwankwanin  (Hausa) and Mgbidim gbe (Igbo), is a 
shrub that is commonly found in West African countries 
especially Nigeria and Ghana [16] [17]. It is an herbaceous, 
perennial twine belonging to the family Asclepiadaceae. It is 
usually woody at the base with 7-8 m in length [19] [20]. 
Parquetina nigrescens have been investigated scientifically 
for quite a number of pharmacological activities. Agbor and 
Odetola, [20] reported that the aqueous extract of P. 
nigrescens leaves increased the red blood cell count of 
anaemic rats. Kayode and Yakubu [21] reported that the 
aqueous extract of P. nigrescens leaves restored both 
physical and biochemical indices of male sexual 
activity/competence via changes in reproductive hormones 
in paroxetin-induced sexually dysfunction rats. Saba et al., 
[22] also reported that P. nigresence exhibited antidiabetic 
and antihyperlipidemic activity. Furthermore, Agbor and 
Odetola [20] concluded that the plant has modulatory effect 
on the haematological parameters of mice whereas it 
exhibited both cardiotonic and sympathomimetic effects in 
rats [23]. 
Despite all these studies, there has not been any report, in 
the open scientific literature that has addressed the toxicity 
of the aqueous extract of P. nigrescens leaves in 
mifepristone-induced PCOS female rats. Therefore, the 
present study was aimed at investigating the safety/toxicity 
risk of aqueous extract of P. nigrescens leaves on 
mifepristone-induced PCOS in female rats. 
MATERIAL AND METHODS 
Plant Material 
The leaves of Parquetina nigrescens were obtained from the 
premises of Wesley University, Ondo, Nigeria. The plant was 
authenticated at the Department of Plant Biology, University 
of Ilorin, Ilorin, Nigeria. A voucher specimen (UIH 
001/0980) was deposited at the Herbarium of the 
Department. 
Animals 
Sixty, healthy, female Wistar rats (190.00 ± 13.00 g) 
obtained from the animal holding Unit of the Department of 
Physiology, University of Ibadan, Ibadan, Nigeria. The 
animals were kept in a well-ventilated house condition 
(temperature: 22±3
o
C; photoperiod: 12h/12h light/dark 
cycle; humidity: 45-50 %) and fed with rat pellets (Vital 
Feeds, Grand Cereals, Jos, Nigeria) and water ad libitum.  
Drugs, Assay Kits, and Chemicals 
Albumin, bilirubin, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), urea, uric acid, creatinine 
and protein assay kits were products of Randox Laboratory, 
Co-Atrim, United Kingdom.  Mifepristone was a product of 
Ranbaxy Laboratories Limited, New Delhi, India. Pure olive 
oil was a product of Andalu-Cia, Goya en Espana, Sevilla, 
Spain. All other reagents used were from Sigma Chemicals, 
St. Louis, USA. 
Preparation of Extract 
A known weight (3 kg) of Parquetina nigrescens leaves was 
washed, air-dried and pulverized in a blender (Mikachi 
Blender, Model MK-1830, China).  The powdered material (1 
kg) was extracted in 5 L of distilled water for 48 hours and 
filtered with Whatman No. 1 filter paper.  The filtrate was 
lyophilized to give a yield of 118.01 g which corresponded to 
11.80%.  The resulting powder was reconstituted in distilled 
water to obtain the doses of 50, 100, 200 mg/kg body weight 
used in this study. 
Animal grouping and extract administration for 
pharmacological study 
A total of 60 female rats that was acclimatized for 2 weeks 
and were completely randomized into six groups of ten (10) 
animals each. PCOS was induced in forty female Wistar rats 
in groups designated B - F with 10 mg of mifepristone as 
described by Yakubu et al. [24].  The extract administration 
according to the groups was carried out as follows:  
Group A (non-PCOS-induced control) received 0.5 ml of 
distilled water 
Group B (PCOS-induced) received 0.5 ml of distilled water 
Group C (PCOS-induced) received 7.14 mg/kg body weight 
of metformin (Reference drug  
Group D (PCOS-induced) received 50 mg/kg body weight of 
aqueous extract of Parquetina nigresens leaves 
Group E (PCOS-induced) received 100 mg/kg body weight of 
aqueous extract of Parquetina nigresens leaves 
 Group F (PCOS-induced) received 200 mg/kg body weight 
of aqueous extract of Parquetina nigresens leaves 
The 0.5 ml of the plant extract and distilled water which 
corresponded to their respective doses were administered 
once daily for thirty days.  At the end of the experimental 
period, the animals were anesthesized using diethyl ether 
and sacrificed by jugular puncture. Thereafter, the uterus, 
liver and kidney were isolated and separately fixed in 10% 
formalin for histological studies. 
Preparation of Serum and Tissue Supernatants 
The method described by Yakubu et al. [25] was used to 
prepare the serum and tissue supernatant.  The rats were 
weighed individually and thereafter anaesthesized in a jar 
containing cotton wool soaked in diethyl ether.  The neck 
area was cleared of fur and skin to expose the jugular veins.  
The jugular veins were displaced slightly from the neck 
region and thereafter cut with a sharp sterile blade. The 
animals were held head downwards, allowed to bleed into 
clean, dry centrifuge tubes and left at room temperature for 
10 minutes to clot.  The blood samples were centrifuged at 
1000 × g for 15 minutes using Uniscope Laboratory 
Centrifuge (Model SM800B, Surgifield Medicals, Davon, 
England).  The sera were thereafter aspirated using Pasteur 
pipette into clean, dry, sample bottles and were then stored 
frozen (4oC) overnight.  The animals were quickly dissected, 
the liver, kidney, uterus and ovary were excised, cleaned of 
fatty layers, weighed and transferred into ice cold 0.25 M 
sucrose solution. Thereafter, each organ were blotted with 
blotting paper, cut thinly with a sterile blade and 
homogenized separately in ice cold 0.25 M sucrose solution 
(1:5 w/v).  The homogenates obtained were centrifuged at 
503 × g for 15 minutes to obtain the supernatants which 
were then gently collected into sample bottles, stored frozen 
(4oC) overnight before being used for the various 
biochemical assays. 
Determination of Biochemical Parameters  
The concentrations of albumin, globulin, total and 
conjugated bilirubin, urea, uric acid, creatinine, ALP, , AST, 
and ALT were determined by adopting standard procedures 
[26].  
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Histopathological Examination  
The organs of interest (liver, kidney and uterus) were fixed 
in 10% (v/v) formaldehyde and processed as described by 
Krause [27], while tissue sectioning was done according to 
the procedure described by Drury and Wallington [28] and 
stained with hematoxylin/ eosin (H and E). 
Photomicrographs of the liver, kidney, ovaries and uterus 
were captured at ×400 with a light microscope connected to 
a computer with Presto! Image Folio package software 
(Newsoft Technology Corporation, USA).  
Statistical Analysis  
Data were expressed as the mean ± standard error mean of 
ten determinations and data were analysed for statistical 
significant at P < 0.05 using One Way Analysis of Variance 
and Duncan Multiple Range Test performed with Statistical 
Package for Social Sciences, version 18.0 (SPSS Inc., Chicago, 
USA). 
RESULTS 
Mifepristone administration significantly (p<0.05) increased 
the serum albumin, globulin, total bilirubin and total protein. 
In contrast, serum conjugated bilirubin and Creatinine of 
mifepristone-treated animals was significantly (p<0.05) 
decreased when compared with the control female rats 
(Table 1). The serum urea and uric acid levels of 
mifepristone-treated female rats compared favourably 
(p>0.05) with control animals (Table 1).All the doses of the 
extract administered significantly (p<0.05) increased the 
serum albumin, total bilirubin and total protein of 
mifepristonized rats whereas the serum globulin and 
creatinine were significantly (p<0.05) decreased compared 
to the control group. However, the reference drug 
administered to mifepristonized rats significantly (P<0.05) 
increased the serum albumin, total protein and uric acid 
whereas the serum globulin, total and conjugated bilirubin 
content decreased significantly when compared with the 
control rats (Table 1). The serum urea concentration of 
mifepristonized rats administered the reference drug and 50 
mg/kg body of AEPNL compared favourably (p>0.05) with 
control animals whereas 100 and 200 mg/kg body of AEPNL 
significantly (P<0.05) elevated urea concentration of 
mifepristonized rats (Table 1). The administration of 50 and 
200 mg/kg body of AEPNL to mifepristonized rats did not 
alter the conjugated bilirubin concentration whereas 100 
mg/kg body of the extract significantly (P<0.05) decreased 
serum conjugated bilirubin content of mifepristonized rats 
when compared with control rats (Table 1). 
The administration of 50 and 200 mg/kg body weight of the 
extract to mifepristone-treated rats significantly (P<0.05) 
increased the ALP activity in the kidney in a manner similar 
to mifepristone-treated rats that were administered 7.14 
mg/kg body weight of metformin. Again, the administration 
of 100 mg/kg body weight of the extract to mifepristone-
treated rats significantly (P<0.05) decreased the ALP activity 
in the kidney when compared with the animals that were 
administered metformin (Table 2). 
However, administration of mifepristone significantly 
(P<0.05) decreased alkaline phosphatase (ALP) activity in 
the liver and serum of animals whereas it significantly 
increased (P<0.05) the kidney enzyme when compared with 
the control female rats (Table 2). The ALP activity in the 
liver of mifepristonized animals administered all the doses 
of the extract was significantly (P<0.05) increased when 
compared to the animals that received metformin (Table 2). 
The ALP activity in the serum of mifepristone-treated 
animals administered 100 and 200 mg/kg body weight of 
the extract was not significantly different (P>0.05) when 
compared to the animals that received metformin whereas 
the 50 mg/kg body weight of the extract significantly 
(P<0.05) decreased the ALP activity in the serum of the 
animals (Table 2).  
The alanine aminotransferase (ALT) activity in the liver and 
serum of the rats administered mifepristone was not 
significantly different (p>0.05) when compared to the 
control female rats. Futhermore, administration of all the 
doses of the extract to mifepristonized rats significantly 
(P<0.05) reduced the ALT activity in the liver when 
compared with animals given metformin, (Table 3). Again, 
administration of 50 and 100 mg/kg body weight of the 
extract to mifepristonized rats significantly (P<0.05) 
increased the ALT activity in the serum when compared with 
the animals administered metformin. The serum ALT 
activity of mifepristone-treated rats that received 200 
mg/kg body weight of the extract was significantly (P<0.05) 
decreased when compared with animals given metformin 
(Table 3). Mifepristone administration to animals 
significantly (p<0.05) reduced the aspartate 
aminotransferase (AST) activity in the liver whereas AST 
activity was not significantly different (p>0.05) in the serum 
when compared with the olive oil-treated female rats. Again, 
administration of all the doses of the extract to 
mifepristonized rats significantly (p<0.05) reduced the AST 
activity in the liver. The activity of AST in mifepristonized 
rats that received 7.14 mg/kg of metformin was significantly 
(p<0.05) increased when compared to the olive oil-treated 
female rats (Table 3). Furthermore, administration of 50 and 
100 mg/kg body weight of the extract to mifepristone-
treated rats significantly (P<0.05) increased the serum AST 
activity in a manner similar to animals that received 
metformin. However, the serum AST activity of 
mifepristonized animals administered 200 mg/kg body 
weight of the extract was significantly decreased when 
compared (P<0.05) with the metformin treated rats (Table 
3). 
The architecture of the liver and kidney was normal at the 
cellular level in distilled water treated control animals (Plate 
1 and 7 respectively). The liver and kidney histoarchitecture 
of female animals administered mifepristone was intact 
(Plate 2 and 8 respectively). Administration of 50, 100 and 
200 mg/kg body weight of the extract and metformin to 
mifepristonized animals revealed the histoarchtecture of 
kidney have normal glomeruli and proximal and distal 
convoluted tubules (Plates 9-12). The liver architecture of 
mifepristonized administered animals 50, 100 and 200 
mg/kg body weight of the extract and metformin was 
normal having hepatocytes with no evidence of adhesion or 
inflammation (Plates 3-6).  
The uterine histoarchitecture of distilled water treated 
control animals were in normal proliferative phase. The 
administration of mifepristone to female animals did not 
distort uterine architecture. Furthermore, mifepristonized 
female rats administered all the doses of the extract and 
metformin had normal uterine epithelium lining. The 
mifepristonized animals administered 50 mg/kg body 
weight of the extract had short cuboidal lining epithelium in 
its histoarchitecture (Plates 13-18). 
 
 
Femi-olabisi et al                                                                                               Journal of Drug Delivery & Therapeutics. 2020; 10(2-s):94-101  
ISSN: 2250-1177                                                                                  [97]                                                                                 CODEN (USA): JDDTAO 
Table 1: Effect of aqueous extract of Parquetina nigresens leaves on some liver and kidney function parameters of 
PCOS rats 
Serum parameter Control MFP + 
distilled 
water 
MFP + 
Metformin 
(7.14 
mg/kg 
body 
weight) 
MFP  + 
50mg/kg 
body weight 
of extract 
MFP  + 
100mg/kg 
body weight 
of extract 
MFP  + 
200mg/kg 
body weight 
of extract 
Albumin (g/dl) 2.16 ± 0.60a 4.33 ± 0.39b 5.61 ± 0.53c 6.32 ±0.41c 6.55 ± 0.33c 11.83 ± 0.58d 
Globulin (g/dl) 7.39 ± 0.61a 7.90 ± 2.44b 5.12 ± 1.00c 4.26 ± 0.89c 3.35 ± 1.13c 5.13 ± 0.59c 
Total Bilirubin 
(µmol/L) 
1.39 ± 0.05a 1.64 ± 0.06b 0.57 ± 0.09d 1.68 ± 0.10b 1.49 ± 0.08b 2.13 ± 0.04c 
Conjugated Bilirubin 
(µmol/L) 
3.04 ± 0.59a 2.13 ± 0.31b 1.84 ± 0.22c 2.39 ± 0.25a 1.94 ± 0.18c 3.33 ± 0.24a 
Total protein (mg/ml) 8.67 ± 0.17a 12.23 ± 2.44b 11.19± 1.08b 10.08 ± 0.40c 10.04 ± 1.10c 16.66 ± 2.46d 
Urea (mg/dl) 9.14 ± 0.60a 9.29 ± 0.54a 9.41 ± 0.31a 9.24 ±0.44a 13.11 ± 0.39b 7.50 ± 0.34c 
Uric acid (mg/dl) 2.24 ± 0.38a 2.16 ± 0.31a 3.14 ± 0.21b 2.47 ± 0.33a 2.77 ± 0.36a 1.37 ± 0.24c 
Creatinine 9.55 ± 0.00a 4.64 ± 0.51b 5.46 ± 0.00b 6.46 ± 0.90b 3.36 ± 0.42b 3.73 ± 1.29b 
Data are means of ten determinations ± SEM.  Values with different superscripts in each column are significantly different 
(P<0.05); MFP- Mifepristone 
 
Table 2: Effects of aqueous extract of P. nigrescens leaves on the alkaline phosphatase activity of the liver, kidney and 
serum of PCOS rats 
Parameter 
 
Control MFP + 
distilled 
water 
MFP + 
Metformin 
(7.14 mg/kg 
body weight) 
MFP  + 
50mg/kg 
body weight 
of extract 
MFP  + 
100mg/kg 
body weight 
of extract 
MFP  + 
200mg/kg 
body weight 
of extract 
Kidney ALP 58.11 ±  0.93a 136.94± 0.58c 223.79± 1.43e 199.93± 0.84d 94.04 ±  6.26b 141.14± 6.68c 
Liver ALP 51.45 ±  3.08a 5.67 ± 0.23e 22.61 ± 0.95d 38.13 ± 1.10c 33.65 ± 2.65c 41.28 ± 0.13b 
Serum ALP 25.26 ± 1.29a 24.02 ± 0.93b 26.53± 1.15c 19.55± 0.44d 27.02± 0.10c 25.65 ± 1.57c 
Data are means of ten determinations ± SEM.  Values with different superscripts in each column are significantly different 
(P<0.05); MFP- Mifepristone, ALP- Alkaline phosphatase 
 
Table 3: Effect of aqueous extract of Parquetina nigrescens leaves on the aminotransferase activity in the liver and 
serum of PCOS rats 
 Parameter 
 
Control MFP + 
distilled 
water 
MFP + 
Metformin 
(7.14 mg/kg 
body weight) 
MFP  + 
50mg/kg 
body weight 
of extract 
MFP  + 
100mg/kg 
body weight 
of extract 
MFP  + 
200mg/kg 
body weight 
of extract 
Liver ALT 45.34±3.71a 36.77±4.09a 47.83±1.96b 27.24±4.56d 27.41±2.98d 14.56±1.68c 
Serum ALT 4.13 ± 0.52a 3.91 ± 0.51a 4.11 ± 0.38a 4.80 ± 0.51b 5.20 ± 0.64b 3.38 ± 0.70a 
Liver AST 118.27±16.58a 55.72 ± 2.16c 169.33± 5.38b 51.75 ± 3.82c 37.37 ± 4.04c 88.27 ± 2.78c 
Serum AST 2.55 ± 0.23a 2.10 ± 0.45a 3.05 ± 0.54b 4.39 ± 0.78b 3.17 ± 0.66b 1.81 ± 0.26a 
Data are means of ten determinations ± SEM.  Values with different superscripts in each column are significantly different 
(P<0.05); MFP- Mifepristone, ALT-Alanine aminotransferase, AST- Aspartate aminotransferase 
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Plate 1: Cross section of the 
liver of female rats 
administered distilled water 
the (control) (×40; H & E) 
Plate 4: Cross section of the liver of 
PCOS rats administered 50 mg/kg 
body weight of aqueous extract of P. 
nigrescens leaves (×40; H & E) 
Plate 2: Cross section of the liver 
of PCOS rats administered 0.5 ml 
of distilled water (×40; H & E) 
Plate 3: Cross section of the liver 
of PCOS rats administered 7.14 
mg/kg body weight of metformin 
(×40; H & E) 
Plate 5: Cross section of the liver of 
PCOS rats administered 100 mg/kg 
body weight of aqueous extract of P. 
nigrescens leaves (×40; H & E) 
Plate 6: Cross section of the liver of 
PCOS reated rats administered 200 
mg/kg body weight of aqueous 
extract of P. nigrescens leaves (×40; 
H & E) 
Plate 7: Cross section of the kidney 
of female rats administered distilled 
water (×40; H & E). 
Plate 8: Cross section of the kidney of 
PCOS rats administered 0.5 ml of 
distilled water (×400; H & E) 
Plate 9: Cross section of the kidney of 
PCOS rats administered 7.14 mg/kg body 
weight of metformin (×400; H & E) 
Plate 10: Cross section of the kidney of 
PCOS administered 50 mg/kg body 
weight of aqueous extract of P. 
nigrescens leaves (×400; H & E) 
Plate 11: Cross section of the kidney of 
PCOS administered 100 mg/kg body 
weight of aqueous extract of P. 
nigrescens leaves (×400; H & E) 
Plate 12: Cross section of the kidney 
of PCOS rats administered 200 
mg/kg body weight of aqueous 
extract of P. nigrescens leaves (×400; 
H & E) 
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DISCUSSION 
The toxicological evaluation of aqueous extract of Parquetina 
nigresens leaves on mifepristone-induced polycystic ovarian 
syndrome in female Wistar rats has provided additional 
information on its effects on the liver and kidney of the 
animals. The importance of evaluating the levels of albumin, 
globulin, and bilirubin (total and conjugated) in the serum of 
animals following the administration of chemical compounds 
including this plant extract cannot be overemphasized as 
they are useful criteria for assessing not only the secretory 
ability and or functional capacity of the liver but also the 
types of liver damage [29]. Albumin, total bilirubin and 
globulin which constitute protein content of the cell can be 
used to assess the functional capacity of the liver [30]. 
Furthermore, the changes in the concentrations of albumin, 
globulin and bilirubin in the serum of the animals can serve 
as useful indicators of the synthetic and secretory function of 
the liver and can also be used to ascertain the type of liver 
damage [31] [29]. The reduction in the level of conjugated 
bilirubin and computed albumin-globulin ratio by 
mifepristone in this present study may be attributed to 
mifepristone diminishing the biosynthesis of the conjugated 
bilirubin and albumin-globulin ratio The elevated level of 
albumin, globulin and total bilirubin may further corroborate 
the mifepristone treatment related changes in the female 
rats. The extract at 100 mg/kg body weight completely 
restored/reversed the elevated total bilirubin and globulin 
induced by mifepristone. The absence of changes in total 
protein level by mifepristone and all the doses of the extract 
suggest that the ability of the liver to produce protein was 
not compromised by the animals. The elevated albumin level 
by mifepristone was further aggravated by the 
administration of the extract suggesting a possible 
synergistic action between the drug and the extract in this 
study. This might be an indication that the extract also has 
the ability to further alter the biochemical changes initiated 
by the drug, mifepristone, in this instance. Overall, the 
mifepristone-induced functional toxicity was further 
aggravated by the extract in the present study.  
The kidney removes metabolic wastes such as urea, uric acid, 
creatinine, ions and thus maintains the optimum chemical 
composition of body fluids [32]. Blood urea and creatinine 
are considered significant markers of renal dysfunction since 
the concentrations of these metabolites increase in the blood 
during renal diseases, renal damage and/or impaired kidney 
functions [33]. Renal function and physiologic reserve 
involve the ability of the kidney not only to filter and clear 
unwanted substances but also reabsorption of essential 
nutrients [2]. The absence of changes in urea and uric acid 
levels of mifepristone-treated rats suggest that glomerular 
filtration rate was unaffected by mifepristone and the 
administration of the extract at 50 mg/kg body weight and 
200 mg/kg body weight did not induce glomerular filtration 
dysfunction. The elevated urea content of mifepristone-
treated animals that received 100 mg/kg body weight of the 
extract suggests that the extract at this dose might enhance 
or stimulate the synthesis of urea. The elevated uric acid 
level of mifepristone-treated female rats that were 
administered the 50 and 100 mg/kg body weight of the 
extract suggests the extract at these doses might enhance 
uric acid synthesis and reduce its elimination from the body 
of the animals. All these alterations by mifepristone and the 
extract implies an effect on the normal functioning of the 
kidney arising probably from interference with the metabolic 
process of the metabolites, inefficient filtration by the kidney 
and obstruction of the lower urinary tract, impaired 
glomerular and tubular reabsorption [29]. 
Plate 12: Cross section of the uterus of female 
rats administered distilled water (×40; H & E) 
Plate 14: Cross section of the uterus 
of PCOS rats administered distilled 
water (×10; H & E) 
Plate 15: Cross section of the 
uterus of PCOS rats administered 
7.14 mg/kg body weight of 
metformin (×10; H & E) 
Plate 17: Cross section of the uterus of 
PCOS rats administered 100 mg/kg body 
weight of aqueous extract of P. 
nigrescens leaves (×10; H & E) 
Plate 18: Cross section of the uterus of 
PCOS rats administered 200 mg/kg 
body weight of aqueous extract of P. 
nigrescens leaves (×10; H & E) 
Plate 16: Cross section of the uterus of 
PCOS rats administered 50 mg/kg body 
weight of aqueous extract of P. nigrescens 
leaves (×10; H & E) 
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Alkaline phosphatase is an ectoenzyme of the plasma 
membrane and is used to assess the integrity or damage to 
the plasma membrane [34] [35]. A significant reduction in 
the liver ALP activities by the administration of mifepristone 
without a corresponding increase in the activity of the 
enzyme in the serum, could be attributed to either inhibition 
of the enzyme activity at the cellular/molecular level [35], or 
inactivation of the enzyme molecules in situ [36]. The 
significant reduction by all the doses of the extract on ALP 
activity without a corresponding increase in the activity of 
the enzyme in the serum reveals that the extract also has a 
diminishing effect on ALP activity in a manner similar to the 
effect of mifepristone. Elevation of kidney ALP in animals 
administered mifepristone suggest induction of enzymes 
synthesis in the kidney probably by de novo or loss of other 
proteins from the tissues [36] and the administration of 50 
and 200 mg/kg body weight of the extract with 
corresponding decrease in serum ALP suggests that the 
extract also has the potential of further inducing ALP 
synthesis in the kidney.  
The absence of an effect on the liver and serum ALT activity 
of animals administered mifepristone suggests that the 
compound has no damaging effect on the hepatocytes. The 
reduction in the liver ALT in mifepristone-treated animals 
administered all the doses of the extract shows that the 
extract attenuated ALT activity and this may be due to 
inactivation of the enzyme molecule while the increase in the 
serum enzyme at 50 and 100 mg /kg body weight of the 
extract may be due to the contribution probably from other 
organs not investigated in the present study.  
The significant reduction in liver AST activity without 
corresponding change in serum AST activity of female rats 
treated with mifepristone suggests enzyme inactivation by 
the compound. The further mitigation of liver AST by the 
administration of all the extract doses to mifepristone-
treated rats suggest enzyme inactivation while the increase 
in serum AST at 50 and 100 mg/kg body weight of the 
extract suggest that the extract at these doses can elevate the 
diminished mifepristone-induced AST activity and this could 
be due to contribution probably from other organ not 
investigated. 
Histological observations provide a microscopic picture of 
the effects produced by the interactions of the 
phytochemicals with the body cells [37]. The preserved liver 
architecture in animals treated with mifepristone suggests 
no structural alteration of the hepatocytes and the 
administration of all the doses of the extract did not 
compromise the hepatocellular structural integrity. The 
absence of gross abnormality or histopathological changes 
following the administration of mifepristone and the 
aqueous extract of P. nigrescens leaves to animals suggests 
that there was no treatment-related structural changes in the 
liver, kidney and uterus. 
CONCLUSION 
In conclusion, AEPNL aggravated mifepristone-treatment 
related increases in albumin, total protein and liver aspartate 
aminotransferase activity and reduced the increases in 
globulin, total bilirubin, urea, creatinine, liver and serum 
alkaline phosphatase and alanine aminotransferase 
activities. However, the 100 mg/kg body weight of the 
extract attenuated the effect of mifepristone on the liver and 
kidney of the female Wistar rats and there is no treatment-
related histoarchitectural changes occurred in the liver, 
kidney and uterus of the female rats. 
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